Value-based medicine has become the center of the new approach to delivering health care in the United States. Today’s “Value-Based Medicine in the Era of Precision Medicine” session will look at various perspectives on the concept of value-based medicine and explore the models currently used in the United States and Europe and the current challenges and impact on the future practice in hepatology and liver transplantation, according to program chair Zobair M. Younossi, MD, MPH, FAASLD.
“Value-based care has actually been more prominently emphasized in some other countries,” said Dr. Younossi. “Historically, US health care providers (physicians and hospitals) have been paid for the volume of patients and the number of procedures and tests that were performed. There was little emphasis on quality and patient outcome. This approach is rapidly changing. In this context, we must deliver high value care to our patients. This means delivering care must be based on best evidence to improve outcome and quality but also in optimizing the total cost of care. It is important to note that value-based care does not always mean cheaper care. In fact, there are instances when you have to invest first to get the best outcome and quality. Nevertheless, in the long run, if you deliver high quality care with the best outcome, you will reduce health care costs to patients and to society”.
Dr. Younossi noted that the value equation not only includes hard outcomes such as patients’ survival, but also their experience with their disease or treatment as indicated by their quality of life and other quality measures and the total cost of care.
This session is designed to help bring hepatologists up to date on the concepts of value-based medicine and inspire development of strategies leading not only to the best clinical outcomes, but also to develop quality measures for a variety of liver diseases. “This session will not only introduce concepts of value-based medicine but also provide implementation strategies to help move hepatologists from a volume-based care to value-based care and payment in hepatology,” said Dr. Younossi.
The session will begin with an introduction to value-based medicine for hepatologists and examples of implementation in the United States and Europe.
“What we also wanted to do is not only bring in the perspective from clinicians and clinical investigators, but also from the payer perspective,” said Dr. Younossi.
In addition to clinicians, the session will appeal to policymakers and health services researchers and industry leaders who are interested in bringing the best value of their services and products to patients.
“At the end of the day you are delivering the best care with the best clinical outcomes and best patient-reported outcomes at the best cost to the patient and to society,” said Dr. Younossi.
1:00 pm – 3:00 pm Today
CC: Ballroom A